Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)

BIOLOGICAL2 trials

Sponsors

University of Minnesota

Conditions

COVIDCOVID-19Covid19SARS (Severe Acute Respiratory Syndrome)SARS-CoV-2SARS-CoV2 Infection

Phase 3

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

CompletedNCT04546581

University of MinnesotaCOVID, COVID-19, SARS-CoV-2 +1

Start: 2020-10-08End: 2021-05-21Updated: 2022-04-04

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

TerminatedNCT04910269

University of MinnesotaCOVID, Covid19, SARS-CoV2 Infection

Start: 2021-08-06End: 2026-06-14Updated: 2026-08-13

Related Papers

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.

2023-03-102 citations

Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection.

2022-10-104 citations

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.

2022-01-2855 citations

Production of anti‐SARS‐CoV‐2 hyperimmune globulin from convalescent plasma

Transfusion2021-03-1448 citations